{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"NRTI Selection when Avoiding Non-Infectious Co-Morbidities of HIV - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"a3afuO9Mew\"><a href=\"https:\/\/themedicalxchange.com\/en\/2011\/10\/12\/13th-european-aids-clinical-society-eacs-confere-2\/\">NRTI Selection when Avoiding Non-Infectious Co-Morbidities of HIV<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2011\/10\/12\/13th-european-aids-clinical-society-eacs-confere-2\/embed\/#?secret=a3afuO9Mew\" width=\"600\" height=\"338\" title=\"&#8220;NRTI Selection when Avoiding Non-Infectious Co-Morbidities of HIV&#8221; &#8212; The Medical Xchange\" data-secret=\"a3afuO9Mew\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2011\/10\/EACS_Figure_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Belgrade - Typical of recent scientific conferences on human immunodeficiency virus (HIV), non-infectious co-morbidities of HIV, particularly age-related processes, consumed much of the focus at this year&rsquo;s EACS conference. New EACS guidelines distributed at the meeting (also available at www.europeanaidsclinicalsociety.org) include substantial attention to these topics, including bone mineral density loss, kidney disease, and cardiovascular risk. Selection of nucleoside reverse transcriptase inhibitor (NRTI) backbones, like the selection of drugs from other classes used in HIV control, is being increasingly based on risk of non-infectious complications relative to the specific risk profile of the patient. This was reflected throughout the EACS conference but was most vividly highlighted in a debate in which three case studies, representing different sets of risks for non-infectious co-morbidities, provided a forum to identify the issues most important for drug selection."}